Travere Therapeutics (TVTX) closed at $50.65 on November 13, 2026, down 1.8% from the previous close, on volume of 661,848 shares (30-day average 2,195,154).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Diagonal Put Spread | 15-Jan-27 : 21-Jan-2850 : 47.5 P | 1,508 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Travere Earnings Call Highlights FILSPARI Growth and Pipeline Momentum
TipRanks (Sat, 14-Nov 9:54 PM ET)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 12-Nov 5:00 PM ET)
Travere Therapeutics to Participate at Upcoming Investor Conferences
Business Wire (Tue, 3-Nov 4:30 PM ET)
Travere Therapeutics Reports Third Quarter 2026 Financial Results
Business Wire (Mon, 2-Nov 4:01 PM ET)
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Business Wire (Mon, 26-Oct 4:30 PM ET)
Business Wire (Fri, 23-Oct 7:20 PM ET)
Business Wire (Fri, 2-Oct 10:00 AM ET)
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
PRNewswire (Wed, 30-Sep 9:58 AM ET)
Business Wire (Wed, 23-Sep 7:00 AM ET)
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Business Wire (Mon, 21-Sep 4:05 PM ET)
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics trades on the NASDAQ stock market under the symbol TVTX.
As of November 13, 2026, TVTX stock price declined to $50.65 with 661,848 million shares trading.
TVTX has a beta of 1.61, meaning it tends to be more sensitive to market movements. TVTX has a correlation of 0.13 to the broad based SPY ETF.
TVTX has a market cap of $4.71 billion. This is considered a Mid Cap stock.
Last quarter Travere Therapeutics reported $225 million in Revenue and -$.31 earnings per share. This beat revenue expectation by $30 million and missed earnings estimates by -$.59.
In the last 3 years, TVTX traded as high as $68.73 and as low as $5.12.
The top ETF exchange traded funds that TVTX belongs to (by Net Assets): VTI, XBI, IWM, VXF, VB.
TVTX has outperformed the market in the last year with a price return of +49.5% while the SPY ETF gained +13.4%. However, in the short term, TVTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -17.5% vs -2.8% return in SPY. But in the last 2 weeks, TVTX shares have fared better than the market returning +0.5% compared to SPY -0.2%.
TVTX support price is $49.66 and resistance is $53.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVTX shares will trade within this expected range on the day.